GMEDNYSESurgical & Medical Instruments & ApparatusFiscal year ends December 31
GLOBUS MEDICAL INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$75.65−1.06 (-1.38%)
Close on Oct 19, 2026
- Market cap
- $10.39B
- P/E (TTM)
- 19.3
- Dividend yield
- –
GLOBUS MEDICAL INC revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Musculoskeletal Solutions | $2.80B | $2.37B | $1.45B | – | – | – | – | – | – | – | 95.2% | +18.3% |
| Enabling Technologies | $141.01M | $154.00M | $120.22M | – | – | – | – | – | – | – | 4.8% | -8.4% |
| Disruptive Technology | – | – | – | – | – | – | – | – | $308.59M | $276.40M | – | – |
| Innovative Fusion | – | – | – | – | – | – | – | – | $327.39M | $287.59M | – | – |
| Musculoskeletal Solutions [Member] | – | $2.37B | $1.45B | $926.70M | $876.78M | $748.45M | $738.38M | $666.04M | $625.06M | – | – | – |
| Enabling Technologies [Member] | – | $154.00M | $120.22M | $96.14M | $81.32M | $40.60M | $46.99M | $46.93M | $10.92M | – | – | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $2.37B | $2.00B | $1.28B | $871.94M | $819.57M | $664.45M | $647.68M | $593.88M | $529.88M | $500.23M | 80.6% | +18.4% |
| International | $571.34M | $519.29M | $288.71M | $150.90M | $138.53M | $124.59M | $137.69M | $119.09M | $106.10M | – | 19.4% | +10.0% |
| International | – | – | – | – | – | – | – | $119.09M | $106.10M | $63.77M | – | – |
From the segment and revenue-disaggregation notes of Globus Medical's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.